Betahistine for symptoms of vertigo

贝塔希丁 眩晕 医学 安慰剂 耳鸣 科克伦图书馆 荟萃分析 随机对照试验 物理疗法 儿科 外科 听力学 内科学 替代医学 病理
作者
Louisa Murdin,K Hussain,Anne G. M. Schilder
出处
期刊:The Cochrane library [Elsevier]
被引量:82
标识
DOI:10.1002/14651858.cd010696.pub2
摘要

Vertigo is a symptom in which individuals experience a false sensation of movement. This type of dizziness is thought to originate in the inner ear labyrinth or its neural connections. It is a commonly experienced symptom and can cause significant problems with carrying out normal activities. Betahistine is a drug that may work by improving blood flow to the inner ear. This review examines whether betahistine is more effective than a placebo at treating symptoms of vertigo from different causes.To assess the effects of betahistine in patients with symptoms of vertigo from different causes.The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. We also contacted manufacturers and researchers in the field. The date of the search was 21 September 2015.We included randomised controlled trials of betahistine versus placebo in patients of any age with vertigo from any neurotological diagnosis in any settings.We used the standard methodological procedures expected by Cochrane. Our primary outcome was the proportion of patients with reduction in vertigo symptoms (considering together the intensity, frequency and duration those symptoms).We included 17 studies, with a total of 1025 participants; 12 studies were published (567 patients) and five were unpublished (458 patients). Sixteen studies including 953 people compared betahistine with placebo. All studies with analysable data lasted three months or less. The majority were at high risk of bias, but in some the risk of bias was unclear. One study, at high risk of bias, included 72 people with benign paroxysmal positional vertigo (BPPV) and compared betahistine with placebo; all patients also had particle repositioning manoeuvres. The studies varied considerably in terms of types of participants, their diagnoses, the dose of betahistine and the length of time it was taken for, the study methods and the way any improvement in vertigo symptoms was measured. Using the GRADE system, we judged the quality of evidence overall to be low for two outcomes (proportion of patients with improvement and proportion with adverse events).Pooled data showed that the proportion of patients reporting an overall reduction in their vertigo symptoms was higher in the group treated with betahistine than the placebo group: risk ratio (RR) 1.30, 95% confidence interval (CI) 1.05 to 1.60; 606 participants; 11 studies). This result should be interpreted with caution as the test for statistical heterogeneity as measured by the I(2) value was high.Adverse effects (mostly gastrointestinal symptoms and headache) were common but medically serious events in the study were rare and isolated: there was no difference in the frequency of adverse effects between the betahistine and placebo groups, where the rates were 16% and 15% respectively (weighted values, RR 1.03, 95% CI 0.76 to 1.40; 819 participants; 12 studies).Sixteen per cent of patients from both the betahistine and the placebo groups withdrew (dropped out) from the studies (RR 0.96, 95% CI 0.65 to 1.42; 481 participants; eight studies).Three studies looked at objective vestibular function tests as an outcome; the numbers of participants were small, techniques of measurement very diverse and reporting details sparse, so analysis of this outcome was inconclusive.We looked for information on generic quality of life and falls, but none of the studies reported on these outcomes.Low quality evidence suggests that in patients suffering from vertigo from different causes there may be a positive effect of betahistine in terms of reduction in vertigo symptoms. Betahistine is generally well tolerated with a low risk of adverse events. Future research into the management of vertigo symptoms needs to use more rigorous methodology and include outcomes that matter to patients and their families.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
妮妮发布了新的文献求助10
2秒前
2秒前
hijack发布了新的文献求助10
3秒前
3秒前
赘婿应助YC采纳,获得10
5秒前
帅气的铭完成签到,获得积分10
6秒前
wanci应助LiuYinglong采纳,获得10
6秒前
7秒前
ardejiang发布了新的文献求助10
7秒前
8秒前
只要平凡发布了新的文献求助10
8秒前
orixero应助爱听歌笑寒采纳,获得10
9秒前
9秒前
大模型应助Mercury采纳,获得10
9秒前
wanci应助耍酷的白山采纳,获得10
10秒前
10秒前
11秒前
12秒前
yue发布了新的文献求助10
12秒前
Lllllllll发布了新的文献求助10
13秒前
hijack完成签到,获得积分10
14秒前
14秒前
14秒前
14秒前
LILI发布了新的文献求助10
15秒前
15秒前
NexusExplorer应助017采纳,获得30
15秒前
Yasmine关注了科研通微信公众号
16秒前
英俊的铭应助ardejiang采纳,获得10
16秒前
lzx发布了新的文献求助10
16秒前
16秒前
fbsnbgfn完成签到,获得积分10
17秒前
j_发布了新的文献求助10
17秒前
zhaxiao发布了新的文献求助10
19秒前
dbzdq发布了新的文献求助10
19秒前
19秒前
Cola完成签到,获得积分10
19秒前
19秒前
yan完成签到 ,获得积分10
20秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154330
求助须知:如何正确求助?哪些是违规求助? 2805172
关于积分的说明 7863751
捐赠科研通 2463360
什么是DOI,文献DOI怎么找? 1311251
科研通“疑难数据库(出版商)”最低求助积分说明 629543
版权声明 601821